Literature DB >> 29215933

A randomized phase II trial of induction chemotherapy followed by cisplatin chronotherapy versus constant rate delivery combined with radiotherapy.

P X Zhang1, F Jin2,3, Z L Li2,3, W L Wu2,3, Y Y Li2,3, J H Long2,3, G Y Chen2,3, X X Chen3, J Y Gan3, X Y Gong3, Q Y He3, T Bi2,3.   

Abstract

Chronotherapy is no longer a novel concept in cancer treatment after approximately 20 years of development. Many clinical trials have provided strong supporting evidence that chronomodulated treatment yields better results than a traditional dosage regimen. This study aimed to evaluate the adverse reactions, effect on immune functions, and therapeutic efficacy of chronomodulated infusion versus flat intermittent infusion of cisplatin (DDP) combined with intensity-modulated radiation therapy (IMRT) in patients with locoregionally advanced nasopharyngeal carcinoma (NPC). A total of 148 patients with biopsy-diagnosed untreated stage III-IVb NPC were randomly assigned to undergo two cycles of chronomodulated infusion (study group) or flat intermittent infusion (control group) of DDP (100 mg/m2 on day 1, 21 days/cycle) synchronized with radical radiotherapy. Patients in the study group received chronomodulated infusion, with peak delivery of DDP at 16:00 pm. Patients in the control group received a routine constant rate of infusion. Both groups were treated with the same radiotherapy techniques. Over a median follow-up of 20 months, the study group had better outcomes for adverse effects and immune functions compared with the control group. During the phase of concurrent chemoradiotherapy, the incidence of nausea, vomiting, and oral mucositis in the study and control groups was 66.7% and 79.5% (p < 0.05), 47.9% and 71.2% (p < 0.05), and 73.9% and 87.7% (p < 0.05), respectively. There was no significant difference in 2-year overall survival, progression-free survival, and distant metastasis-free survival between the two groups (p > 0.05). Chronochemotherapy significantly reduced the incidence of adverse reactions and enhanced the tolerance for treatment without affecting survival. It is worth mentioning that reduced destruction of immune function is a novel area of exploration in chronotherapy research.

Entities:  

Keywords:  Chronochemotherapy; Nasopharyngeal carcinoma; cisplatin; radiotherapy

Mesh:

Substances:

Year:  2017        PMID: 29215933     DOI: 10.1080/07420528.2017.1397684

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  9 in total

1.  Circadian disruption and cisplatin chronotherapy for mammary carcinoma.

Authors:  Bala S C Koritala; Kenneth I Porter; Soumyadeep Sarkar; Shobhan Gaddameedhi
Journal:  Toxicol Appl Pharmacol       Date:  2022-01-05       Impact factor: 4.219

Review 2.  Circadian Rhythms, Disease and Chronotherapy.

Authors:  Yool Lee; Jeffrey M Field; Amita Sehgal
Journal:  J Biol Rhythms       Date:  2021-09-22       Impact factor: 3.649

Review 3.  Exploring the link between chronobiology and drug delivery: effects on cancer therapy.

Authors:  Tânia Albuquerque; Ana R Neves; Telma Quintela; Diana Costa
Journal:  J Mol Med (Berl)       Date:  2021-07-02       Impact factor: 4.599

Review 4.  Circadian Variation in Efficacy of Medications.

Authors:  James C Walton; William H Walker; Jacob R Bumgarner; O Hecmarie Meléndez-Fernández; Jennifer A Liu; Heather L Hughes; Alexis L Kaper; Randy J Nelson
Journal:  Clin Pharmacol Ther       Date:  2020-11-29       Impact factor: 6.903

Review 5.  Chronodentistry: the role & potential of molecular clocks in oral medicine.

Authors:  Klara Janjić; Hermann Agis
Journal:  BMC Oral Health       Date:  2019-02-13       Impact factor: 2.757

6.  Exploiting the Circadian Clock for Improved Cancer Therapy: Perspective From a Cell Biologist.

Authors:  Tia Tyrsett Kuo; Andreas G Ladurner
Journal:  Front Genet       Date:  2019-12-11       Impact factor: 4.599

Review 7.  Clock in radiation oncology clinics: cost-free modality to alleviate treatment-related toxicity.

Authors:  Yasser F Ali; Zhiqiang Hong; Ning-Ang Liu; Guangming Zhou
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.742

8.  Polydopamine-modified chitin conduits with sustained release of bioactive peptides enhance peripheral nerve regeneration in rats.

Authors:  Ci Li; Song-Yang Liu; Li-Ping Zhou; Tian-Tian Min; Meng Zhang; Wei Pi; Yong-Qiang Wen; Pei-Xun Zhang
Journal:  Neural Regen Res       Date:  2022-11       Impact factor: 6.058

Review 9.  Chronodisruption and Ambulatory Circadian Monitoring in Cancer Patients: Beyond the Body Clock.

Authors:  Pedro F Almaida-Pagan; María Torrente; Manuel Campos; Mariano Provencio; Juan Antonio Madrid; Fabio Franco; Beatriz Rodríguez Morilla; Blanca Cantos; Pedro A Sousa; María José Martínez Madrid; Joao Pimentao; María Ángeles Rol
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.